title: Immunoglobulin deficiencies and susceptibility to infection among homozygotes and heterozygotes for C2 deficiency.
abstract: About 25% of C2-deficient homozygotes have increased susceptibility to severe bacterial infections. C2-deficient homozygotes had significantly lower serum levels of IgG2, IgG4, IgD, and Factor B, significantly higher levels of IgA and IgG3 and levels of IgG1 and IgM similar to controls. Type 1 (28 bp deletion in C2 exon 6 on the [HLA-B18, S042, DR2] haplotype or its fragments) and type II (non-type I) C2-deficient patients with increased susceptibility to bacterial infection had significantly lower mean levels of IgG4 (p < 0.04) and IgA (p < 0.01) than those without infections (who had a higher than normal mean IgA level) but similar mean levels of other immunoglobulins and Factor B. Of 13 C2-deficient homozygotes with infections, 85% had IgG4 deficiency, compared with 64% of 25 without infections. IgD deficiency was equally extraordinarily common among infection-prone (50%) and noninfection-prone (70%) homozygous type I C2-deficient patients. IgD deficiency was also common (35%) among 31 type I C2-deficient heterozygotes (with normal or type II haplotypes), but was not found in 5 type II C2-deficient heterozygotes or 1 homozygote. Thus, C2 deficiency itself is associated with many abnormalities in serum immunoglobulin levels, some of which, such as in IgG4 and IgA, may contribute to increased susceptibility to infection. In contrast, IgD deficiency appears not to contribute to increased infections and appears to be a dominant trait determined by a gene or genes on the extended major histocompatibility complex (MHC) haplotype [HLA-B 18, S042, DR2] (but probably not on type II C2-deficient haplotypes) similar to those previously identified on [HLA-B8, SC01, DR3] and [HLA-B18, F1C30, DR3].
authors.affiliation: The Center for Blood Research, Harvard Medical School, Boston, Massachusetts 02115, USA. alper@cbr.med.harvard.edu
authors.forename: Chester A
authors.initials: CA
authors.lastname: Alper
authors.forename: Jianhua
authors.initials: J
authors.lastname: Xu
authors.forename: Katherine
authors.initials: K
authors.lastname: Cosmopoulos
authors.forename: Brian
authors.initials: B
authors.lastname: Dolinski
authors.forename: Rosanne
authors.initials: R
authors.lastname: Stein
authors.forename: Gabriel
authors.initials: G
authors.lastname: Uko
authors.forename: Charles E
authors.initials: CE
authors.lastname: Larsen
authors.forename: Devendra P
authors.initials: DP
authors.lastname: Dubey
authors.forename: Peter
authors.initials: P
authors.lastname: Densen
authors.forename: Lennart
authors.initials: L
authors.lastname: Truedsson
authors.forename: Gunnar
authors.initials: G
authors.lastname: Sturfelt
authors.forename: Anders G
authors.initials: AG
authors.lastname: Sjöholm
mesh_terms: D003175:Complement C2 / Q000172:deficiency* / Q000235:genetics; D011415:Complement Factor B / Q000032:analysis; D004198:Disease Susceptibility; D004406:Dysgammaglobulinemia / Q000276:immunology*; D006239:Haplotypes; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D017098:IgA Deficiency / Q000276:immunology; D017099:IgG Deficiency / Q000276:immunology; D007072:Immunoglobulin D / Q000172:deficiency; D007136:Immunoglobulins / Q000097:blood; D007239:Infections / Q000209:etiology*
chemical_list: D003175:Complement C2; D007072:Immunoglobulin D; D007136:Immunoglobulins; D011415:Complement Factor B